Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis?
Wendling
Daniel
D
Toussirot
Eric
E
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001857:Bone Matrix / Q000378:metabolism / Q000503:physiopathology*; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000097:blood; D016723:Bone Remodeling / Q000502:physiology*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D016173:Macrophage Colony-Stimulating Factor / Q000097:blood; D019278:Matrix Metalloproteinase 3 / Q000097:blood; D053244:Osteoprotegerin / Q000097:blood; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013167:Spondylitis, Ankylosing / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D016212:Transforming Growth Factor beta / Q000097:blood; D016896:Treatment Outcome
D018501:Antirheumatic Agents; C525819:BMP7 protein, human; D015415:Biomarkers; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D007074:Immunoglobulin G; D053244:Osteoprotegerin; D018124:Receptors, Tumor Necrosis Factor; D016212:Transforming Growth Factor beta; D016173:Macrophage Colony-Stimulating Factor; D019278:Matrix Metalloproteinase 3; D000068800:Etanercept